Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05170256 |
| Title | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (HERES) |
| Acronym | HERES |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Morten Mau-Sorensen |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DNK |